These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 23243180)

  • 21. Using HIV Viral Load From Surveillance to Estimate the Timing of Antiretroviral Therapy Initiation.
    Braunstein SL; Robertson MM; Myers J; Nash D
    J Acquir Immune Defic Syndr; 2016 Oct; 73(2):222-7. PubMed ID: 27152466
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Plasma HIV-1 RNA detection below 50 copies/ml and risk of virologic rebound in patients receiving highly active antiretroviral therapy.
    Doyle T; Smith C; Vitiello P; Cambiano V; Johnson M; Owen A; Phillips AN; Geretti AM
    Clin Infect Dis; 2012 Mar; 54(5):724-32. PubMed ID: 22238167
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relationship between CD4+ T-cell counts/HIV-1 RNA plasma viral load and AIDS-defining events among persons followed in the ACTG longitudinal linked randomized trials study.
    Smurzynski M; Wu K; Benson CA; Bosch RJ; Collier AC; Koletar SL
    J Acquir Immune Defic Syndr; 2010 Sep; 55(1):117-27. PubMed ID: 20622677
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Plasma HIV-2 RNA According to CD4 Count Strata among HIV-2-Infected Adults in the IeDEA West Africa Collaboration.
    Ekouévi DK; Avettand-Fènoël V; Tchounga BK; Coffie PA; Sawadogo A; Minta D; Minga A; Eholie SP; Plantier JC; Damond F; Dabis F; Rouzioux C;
    PLoS One; 2015; 10(6):e0129886. PubMed ID: 26111242
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Viral load in HIV-infected children on high activity antiretroviral therapy].
    Resino S; Bellón JM; León JA; Resino R; Muñoz-Fernández MA;
    Med Clin (Barc); 2007 Jan; 128(2):49-51. PubMed ID: 17266901
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Virologic outcome among patients receiving antiretroviral therapy at five hospitals in Haiti.
    Jean Louis F; Buteau J; François K; Hulland E; Domerçant JW; Yang C; Boncy J; Burris R; Pelletier V; Wagar N; Deyde V; Lowrance DW; Charles M
    PLoS One; 2018; 13(1):e0192077. PubMed ID: 29381736
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of Implementation of a Universal Testing and Treatment Intervention With HIV Diagnosis, Receipt of Antiretroviral Therapy, and Viral Suppression in East Africa.
    Petersen M; Balzer L; Kwarsiima D; Sang N; Chamie G; Ayieko J; Kabami J; Owaraganise A; Liegler T; Mwangwa F; Kadede K; Jain V; Plenty A; Brown L; Lavoy G; Schwab J; Black D; van der Laan M; Bukusi EA; Cohen CR; Clark TD; Charlebois E; Kamya M; Havlir D
    JAMA; 2017 Jun; 317(21):2196-2206. PubMed ID: 28586888
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Implementation and operational feasibility of SAMBA I HIV-1 semi-quantitative viral load testing at the point-of-care in rural settings in Malawi and Uganda.
    Gueguen M; Nicholas S; Poulet E; Schramm B; Szumilin E; Wolters L; Wapling J; Ajule E; Rakesh A; Mwenda R; Kiyaga C; Balkan S
    Trop Med Int Health; 2021 Feb; 26(2):184-194. PubMed ID: 33159822
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A simple self-reported adherence tool as a predictor of viral rebound in people with viral suppression on antiretroviral therapy.
    O'Connor JL; Gardner EM; Esser S; Mannheimer SB; Lifson AR; Telzak EE; Phillips AN;
    HIV Med; 2016 Feb; 17(2):124-32. PubMed ID: 26186609
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005.
    Hoen B; Cooper DA; Lampe FC; Perrin L; Clumeck N; Phillips AN; Goh LE; Lindback S; Sereni D; Gazzard B; Montaner J; Stellbrink HJ; Lazzarin A; Ponscarme D; Staszewski S; Mathiesen L; Smith D; Finlayson R; Weber R; Wegmann L; Janossy G; Kinloch-de Loes S;
    Clin Infect Dis; 2007 Aug; 45(3):381-90. PubMed ID: 17599319
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cellular HIV-1 DNA levels in patients receiving antiretroviral therapy strongly correlate with therapy initiation timing but not with therapy duration.
    Watanabe D; Ibe S; Uehira T; Minami R; Sasakawa A; Yajima K; Yonemoto H; Bando H; Ogawa Y; Taniguchi T; Kasai D; Nishida Y; Yamamoto M; Kaneda T; Shirasaka T
    BMC Infect Dis; 2011 May; 11():146. PubMed ID: 21605468
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of CD8+ T-cell activation on CD4+ T-cell recovery and mortality in HIV-infected Ugandans initiating antiretroviral therapy.
    Hunt PW; Cao HL; Muzoora C; Ssewanyana I; Bennett J; Emenyonu N; Kembabazi A; Neilands TB; Bangsberg DR; Deeks SG; Martin JN
    AIDS; 2011 Nov; 25(17):2123-31. PubMed ID: 21881481
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of antiretroviral triple combinations including the protease inhibitor nelfinavir in heavily pretreated children with HIV-1 infection.
    Hoffmann F; Funk M; Linde R; Notheis G; Petropoulou T; Eberle J; Gürtler L; Belohradsky BH; Wintergerst U
    Eur J Med Res; 2002 Jul; 7(7):330-4. PubMed ID: 12176683
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Accuracy of self-report of HIV viral load among people with HIV on antiretroviral treatment.
    Sewell J; Daskalopoulou M; Nakagawa F; Lampe FC; Edwards S; Perry N; Wilkins E; O'Connell R; Jones M; Collins S; Speakman A; Phillips AN; Rodger AJ;
    HIV Med; 2017 Aug; 18(7):463-473. PubMed ID: 28004523
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Brief Report: Interferon-γ-Inducible Protein 10-A Potential Marker for Targeted Viral Load Monitoring of Antiretroviral Treatment?
    Reepalu A; Arimide DA; Balcha TT; Björkman P; Medstrand P
    J Acquir Immune Defic Syndr; 2020 Apr; 83(5):475-478. PubMed ID: 31917753
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Substance use patterns and HIV-1 RNA viral load rebound among HIV-positive illicit drug users in a Canadian setting.
    Ladak F; Socias E; Nolan S; Dong H; Kerr T; Wood E; Montaner J; Milloy MJ
    Antivir Ther; 2019; 24(1):19-25. PubMed ID: 30230474
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Viral load detection and management on first line ART in rural Rwanda.
    Ndagijimana Ntwali JD; Decroo T; Ribakare M; Kiromera A; Mugwaneza P; Nsanzimana S; Lynen L
    BMC Infect Dis; 2019 Jan; 19(1):8. PubMed ID: 30606128
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Different outcomes in patients achieving complete or partial viral load suppression on antiretroviral therapy.
    de Mendoza C; Soriano V; Pérez-Olmeda M; Rodés B; Casas E; González-Lahoz J
    J Hum Virol; 1999; 2(6):344-9. PubMed ID: 10774551
    [TBL] [Abstract][Full Text] [Related]  

  • 39. How reliable is an undetectable viral load?
    Combescure C; Vallier N; Ledergerber B; Cavassini M; Furrer H; Rauch A; Battegay M; Bernasconi E; Vernazza P; Hirschel B;
    HIV Med; 2009 Sep; 10(8):470-6. PubMed ID: 19459990
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Case Study of an Effective and Sustainable Antiretroviral Therapy Program in Rural South Africa.
    Le Roux KW; Davis EC; Gaunt CB; Young C; Koussa M; Harris C; Rotheram-Borus MJ
    AIDS Patient Care STDS; 2019 Nov; 33(11):466-472. PubMed ID: 31682167
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.